Latest News

Biopharma Co. to Launch Two Clinical Trials This Year

May 16, 2022 ( Newswire) Success in either program, atopic dermatitis or asthma, “could lead to multiblockbuster sales,” noted a ROTH Capital Partners report.

RAPT Therapeutics Inc.’s (RAPT:NASDAQ) “clinical plans remain on track” and the biopharma has the cash to execute on them, reported ROTH Capital Partners analyst Zegbeh Jallah in a May 12th research note. This California-based firm is developing small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases.

RAPT, in reporting its Q1/22 financial and operational results, indicated two Phase 2 trials involving its lead drug candidate in inflammatory diseases, oral CCR4 agonist RPT193, are expected to commence on time, noted Jallah. The study in atopic dermatitis is slated for initiation in H1/22, the trial in asthma, in H2/22.

“Success [in either indication] could lead to multi-blockbuster sales,” Jallah commented.

ROTH’s target price on RAPT, of $72 per share, suggests potential multi-bagger returns, given the stock is now trading at around $12.35 per share.

“We remind investors of the potential attractiveness of RPT193 to a large pharma even while viewing FLX475 as a call option until additional data updates are provided,” added Jallah.

FLX475 is a CCR4 antagonist that RAPT is pursuing in various solid tumors, including head and neck small cell carcinoma, nasopharyngeal cancer, and Epstein-Barr virus-positive lymphoma. Jallah noted that biopharma continues to make progress with these programs “providing additional upside.”

Jallah pointed out that RAPT is well funded to see it at least through 2022, having $173 million in cash, cash equivalents, and marketable securities at the end of Q1/22.

ROTH rates the biopharma a Buy.


1) Doresa Banning compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. She or members of her household own securities of the following companies mentioned in the article: None. She or members of her household are paid by the following companies mentioned in this article: None.

2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees.

3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.

4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of the information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports’ terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services, or securities of any company mentioned on Streetwise Reports.

5) From time to time, Streetwise Reports LLC and its directors, officers, employees, or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in the securities mentioned. Directors, officers, employees, or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the decision to publish an article until three business days after the publication of the article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases.

6) This article does not constitute medical advice. Officers, employees, and contributors to Streetwise Reports are not licensed, medical professionals. Readers should always contact their healthcare professionals for medical advice.

Disclosures for Roth Capital Partners, RAPT Therapeutics, May 12, 2022

Within the last twelve months, ROTH Capital Partners, or an affiliate to ROTH Capital Partners, has received compensation for investment banking services from RAPT Therapeutics. ROTH makes a market in shares of RAPT Therapeutics and as such, buys and sells from customers on a principal basis. Within the last twelve months, ROTH Capital Partners, or an affiliate to ROTH Capital Partners, has managed or co-managed a public offering for RAPT Therapeutics.

Not Covered [NC]: ROTH does not publish research or have an opinion about this security. ROTH Capital Partners, LLC expects to receive or intends to seek compensation for investment banking or other business relationships with the covered companies mentioned in this report in the next three months. The material, information, and facts discussed in this report other than the information regarding ROTH Capital Partners, LLC and its affiliates, are from sources believed to be reliable but are in no way guaranteed to be complete or accurate. This report should not be used as a complete analysis of the company, industry, or security discussed in the report. Additional information is available upon request. This is not, however, an offer or solicitation of the securities discussed. Any opinions or estimates in this report are subject to change without notice. An investment in the stock may involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Additionally, an investment in the stock may involve a high degree of risk and may not be suitable for all investors. No part of this report may be reproduced in any form without the express written permission of ROTH.

More Info:

This news is published on the Newswire – a global digital news source for investors and business leaders

Disclaimer/Disclosure: is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions.

More disclaimer info: Learn more about publishing your news release and our other news services on the newswire and

Global investors must adhere to regulations of each country. Please read privacy policy: – investing ideas in biotechnology stocks, medical technology and life sciences

Like Biotech Stocks? View our Biotech Stocks Directory

Buy a biotech guest post on

What's your reaction?

In Love
Not Sure

You may also like

Leave a reply

Your email address will not be published. Required fields are marked *

More in:Latest News